📊 ELUT Key Takeaways
Is ELUT a Good Investment? Thesis Analysis
Elutia exhibits severe operational dysfunction with massive operating losses (-218.9% margin) despite modest revenue of $12.3M, which declined 15% YoY. The extraordinary net income of $53.4M appears driven by non-operating gains (likely asset sales or accounting adjustments) rather than core business performance, masking deteriorating fundamentals. Negative free cash flow of -$46.7M combined with $26.1M long-term debt and rapidly depleting cash reserves signal an unsustainable burn rate.
Why Buy ELUT? Key Strengths
- Strong liquidity position with $36.4M cash and 2.22x current ratio provides near-term runway
- High gross margin of 53.7% indicates viable product economics at the unit level
- Moderate leverage ratio of 0.94x debt-to-equity provides some balance sheet cushion
ELUT Investment Risks to Consider
- Severe cash burn of $46.7M free cash flow with only 10+ quarters of runway at current burn rate
- Revenue contraction of 15% YoY combined with -218.9% operating margin indicates business is not scaling profitably
- Negative interest coverage of -20.5x indicates inability to service debt from operating earnings; dependent on non-recurring gains
- Operating cash flow of -$44.8M signals core business is destroying rather than generating cash
- Net margin of 434.2% is unrealistic and driven by one-time items, masking true operational performance
Key Metrics to Watch
- Operating cash flow trend and path to cash flow breakeven
- Revenue growth trajectory and customer acquisition/retention rates
- Operating margin improvement and achievement of sustainable profitability
- Cash runway and timeline to additional capital needs
- Composition of net income gains to assess recurrence of reported profits
ELUT Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.22x current ratio provides a solid financial cushion.
ELUT Profitability Ratios
ELUT vs Healthcare Sector
How ELUTIA INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ELUT Overvalued or Undervalued?
Based on fundamental analysis, ELUTIA INC. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ELUT Balance Sheet & Liquidity
ELUT 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: ELUTIA INC.'s revenue has declined by 69% over the 5-year period, indicating business contraction. The most recent EPS of $-1.86 indicates the company is currently unprofitable.
ELUT Growth Metrics (YoY)
ELUT Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $3.3M | $1.3M | $-0.19 |
| Q2 2025 | $6.3M | -$9.6M | $-0.26 |
| Q1 2025 | $6.0M | -$3.9M | $-0.21 |
| Q3 2024 | $5.9M | $1.3M | $-0.33 |
| Q2 2024 | $6.3M | -$10.6M | $-0.65 |
| Q3 2023 | $5.8M | -$8.0M | $-0.49 |
| Q2 2023 | $10.3M | -$9.4M | $-0.65 |
| Q1 2023 | $11.5M | -$8.0M | $-0.49 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ELUT Capital Allocation
ELUT SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for ELUTIA INC. (CIK: 0001708527)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ELUT
What is the AI rating for ELUT?
ELUTIA INC. (ELUT) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ELUT's key strengths?
Claude: Strong liquidity position with $36.4M cash and 2.22x current ratio provides near-term runway. High gross margin of 53.7% indicates viable product economics at the unit level.
What are the risks of investing in ELUT?
Claude: Severe cash burn of $46.7M free cash flow with only 10+ quarters of runway at current burn rate. Revenue contraction of 15% YoY combined with -218.9% operating margin indicates business is not scaling profitably.
What is ELUT's revenue and growth?
ELUTIA INC. reported revenue of $12.3M.
Does ELUT pay dividends?
ELUTIA INC. does not currently pay dividends.
Where can I find ELUT SEC filings?
Official SEC filings for ELUTIA INC. (CIK: 0001708527) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ELUT's EPS?
ELUTIA INC. has a diluted EPS of $0.87.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ELUT a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, ELUTIA INC. has a SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ELUT stock overvalued or undervalued?
Valuation metrics for ELUT: ROE of 192.9% (sector avg: 15%), net margin of 434.2% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy ELUT stock in 2026?
Our dual AI analysis gives ELUTIA INC. a combined SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is ELUT's free cash flow?
ELUTIA INC.'s operating cash flow is $-44.8M, with capital expenditures of $1.9M. FCF margin is -379.8%.
How does ELUT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 434.2% (avg: 12%), ROE 192.9% (avg: 15%), current ratio 2.22 (avg: 2).